Dotinurad: a clinical pharmacokinetic study of a novel, selective urate reabsorption inhibitor in subjects with hepatic impairment

BACKGROUND: Dotinurad is a novel, selective urate reabsorption inhibitor, which reduces serum uric acid levels by inhibiting the urate transporter 1 (URAT1). We compared the pharmacokinetics (PK), pharmacodynamics (PD), and safety of dotinurad in subjects with hepatic impairment and normal hepatic f...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumagai, Yuji, Sakaki, Masashi, Furihata, Kenichi, Ito, Takayoshi, Inoue, Kazuaki, Yoshida, Takafumi, Matsumoto, Shigeki, Furuno, Kazuki, Hagino, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066095/
https://www.ncbi.nlm.nih.gov/pubmed/31760530
http://dx.doi.org/10.1007/s10157-019-01816-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066095/
https://www.ncbi.nlm.nih.gov/pubmed/31760530
http://dx.doi.org/10.1007/s10157-019-01816-4

Ejemplares similares